Danielle Rosato

Danielle N. Rosato

Senior Associate

Danielle Rosato's practice focuses on a wide range of corporate transactions, including mergers and acquisitions, private equity investments, joint ventures, strategic alliances, corporate reorganizations and restructurings, licensing and collaboration arrangements, and manufacturing and supply arrangements. She also advises clients on corporate governance matters.

Ms. Rosato has experience representing both US and non-US companies in a variety of industries, including life sciences, private equity, healthcare, consumer products, and financial services.

Ms. Rosato attended Washington University School of Law, where she served as the Associate Managing Editor of the Washington University Global Studies Law Review and received the Don Sommers Award in Professional Responsibility.


  • Pfizer in the sale to Biogen of a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases.
  • Pfizer in a worldwide licensing agreement with Akcea Therapeutics, a majority owned affiliate of Ionis Pharmaceuticals, granting Pfizer exclusive rights to AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases.
  • Novartis in the sale to Recordati of its endocrine products, including Signifor LAR and in-development follow-up osilodrostat (LCI699) for $390 million plus milestones.
  • Multinational consumer goods company in its acquisition of a founder-owned pre-and post-natal healthcare company.
  • Imbrium Therapeutics, a subsidiary of Purdue Pharma, in its research & development collaboration with TetraGenetics to discover and develop non-opioid biologic therapies for the treatment of chronic pain.
  • Pfizer in its joint creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat central nervous system disorders, with Bain Capital. Pfizer contributed a portfolio of pre-commercial neuroscience assets to Cerevel and retained a 25% equity position, while Bain Capital's affiliated funds committed $350 million with the ability to provide additional capital if needed.
  • Multinational pharmaceutical company in an exclusive OTC switch licensing agreement for the US.
  • Novartis in an expanded commercialization agreement with Amgen, enabling Novartis and Amgen to co-commercialize the first-in-class AMG 334 (erenumab) program, a full human monoclonal antibody designed for migraine prevention, in the US and granting Novartis exclusive commercialization rights in Canada. Novartis also retained exclusive rights to commercialize the drug globally, excluding Japan.
  • Pfizer in its acquisition of Bamboo Therapeutics, a biotechnology company focused on developing gene therapies for the treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system.
  • Novartis in the sale to Vanda Pharmaceuticals of the rights to antipsychotic drug Fanapt® in the US and Canada.
  • Pfizer in a worldwide licensing agreement with OPKO Health, granting Pfizer exclusive rights to develop and commercialize OPKO's long-acting human growth hormone (hGH-CTP) for the treatment of growth hormone deficiency in adults and children, for an upfront payment of $295 million with up to $275 million of contingent milestone payments plus undisclosed royalties.


The Deal Awards Middle Market
"Healthcare & Pharma Deal of the Year" (2019)


  • JD, Washington University School of Law, 2014, cum laude
  • BA, Boston College, 2011, summa cum laude, Phi Beta Kappa
  • New York
  • Florida
  • Member, American Bar Association Section of Business Law

Email Disclaimer